By Dr. Quratulain Badar
Abstract:
(for Oral Presentation/Invited Talk)
Breast cancer radiotherapy experienced a lot of change in past
decade. In era of neoadjuvant chemotherapy and availability of
SLNB, indications of RT has changed significantly. On the
other hand, with reducing surgery in breast cancer,
radiotherapy has to be considered in several cases even in early
stage cancer. Moderate hypo fractionation is now a standard of
care but ultra-hypo fractionation has to be chosen with great
caution and safety measures as there are several points which
can easily be ignored by treating radiation oncologist while
doing ultra-hypo fractionation.
The presenter will cover recent updates, including NSABP-51
trial and will critical appraise trials of ultra-hypo fractionation.